生物标志物在急性肾损伤中的临床研究进展

凯 程(中南大学湘雅医学院，中国)
炳权 吴(中南大学湘雅医学院，中国)

摘要

急性肾损伤（Acute kidney injury, AKI）在危重患者中发生率高，对慢性肾脏病（Chronic kidney disease, CKD）进展、心血管疾病和死亡率均有显著影响。尽管大多数医生会根据血清肌酐的变化进行诊断及治疗，但往往已经是延迟干预。近年来，各种AKI生物标志物被发现并得到验证，提高了对进行性肾功能减退、需要肾替代治疗或死亡高风险患者的及时发现概率，进而区分患者并进行风险分级。本综述将回顾过去十年中经过验证的AKI生物标记物，及其相关的临床适用情况，使用AKI生物标志物来补充现有诊断标准，通过早期识别和临床结果预测，将更好地为患者提供医疗干预。

关键词

急性肾损伤；生物标志物；早期诊断；预后

参考

Herget-rosenthal S, MarggraF G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int, 2004,66(3):1115-1122.

Ahlström A, Tallgren M, Peltonen S, et al. Evolution and predictive power of serum cystatin C in acute renal failure[J]. Clin Nephrol, 2004,62(5):344-350.

Shukla A N, Juneja M, Patel H, et al. Diagnostic accuracy of serum cystatin C for early recognition of contrast induced nephropathy in Western Indians undergoing cardiac catheterization[J]. Indian Heart J,2017,69(3):311-315.

Cai L, Rubin J, Han W. The origin of multiple molecular forms in urine of HNL/NGAL [J]. Clin J Am Soc Nephrol,2010,5(12): 2229-2235.

Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery[J].Lancet,2005,365(9466):1231-1238.

Negrin L L, Hahn R, Heinz T, et al. Diagnostic Utility of Serum Neutrophil Gelatinase-Associated Lipocalin in Polytraumatized Patients Suffering Acute Kidney Injury: A Prospective Study[J].Biomed Res Int,2018:2687584.

Susantitaphong P, Siribamrungwong M, Doi K, et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis[J]. Am J Kidney Dis,2013,61(3):430-439.

Parikh C R, Abraham E, Ancukiewicz M, et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit[J]. J Am Soc Nephrol,2005, 16(10):3046-3052.

Kashani K, Cheungpasitporn W, RONCO C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption[J].Clin Chem Lab Med,2017,55(8):1074-1089.

Hoste E A, Mccullough P A, KASHANI K, et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers [J]. Nephrol Dial Transplant,2014,29(11):2054-2061.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v4i12.9762